40 results about "Fasting insulin" patented technology

A method of controlling an insulin infusion device comprises operating a processor architecture comprising at least one processor device to calculate a maximum insulin infusion rate for the user based on a fasting blood glucose value associated with the user, a total daily insulin value associated with the user, and fasting insulin delivery data that is indicative of insulin delivered to the user during a fasting period, wherein the maximum insulin infusion rate is applicable during a period of closed-loop operation of the insulin infusion device; obtaining a first closed-loop insulin infusion rate for the user, wherein the first closed- loop insulin infusion rate is obtained for a current sampling point during the period of closed- loop operation; and providing a second closed-loop insulin infusion rate for the user when the obtained first closed-loop insulin infusion rate is greater than the calculated maximum insulin infusion rate, wherein the second closed-loop insulin infusion rate is less than the first closed-loop insulin infusion rate; the first closed-loop insulin infusion rate is calculated in accordance with a proportional-integral-derivative insulin feedback (PID-IFB) control algorithm; and inhibiting windup of an integral component of the PID-IFB control algorithm when the obtained first closed-loop insulin infusion rate is greater than the calculated maximum insulin infusion rate.

The invention provides eyesight-improving eye-protecting anti-radiation erythritol chewable tablets. The chewable tablets contain xanthophyll, green tea extract, pollen extract, erythritol, mannitol, high-rate sweetening agent, magnesium stearate and hydroxypropyl methyl cellulose. The chewable tablets have the eyesight-improving eye-protecting and anti-radiation effects and are suitable for being eaten by the crowd who contact with computers for a long time and work and study for a long time. The erythritol-containing chewable tablets have the characteristics that the mouthfeel is cool and refreshing, the heat value is low, decayed tooth is not caused and fluctuation of blood sugar and fasting insulin level is avoided; the defects in the prior art that the chewable tablets are high in heat value and simple in moisture absorption and the blood sugar is increased and decayed tooth is easily caused after the chewable tablets are eaten are overcome.

The invention discloses a buccal tablet applicable to being taken for type II diabetes. The buccal tablet is prepared from the following components in parts by weight: 18-22 parts of island stichopus japonicas sea cucumber fucoidan chitosan sulfate, 17-19 parts of astragalus polysaccharide, 14-16 parts of rehmannia extract, 15-16 parts of tremella polysaccharide, 9-12 parts of microcrystalline cellulose, 7-9 parts of newtol, 7-9 parts of magnesium stearate, 4-5 parts of sodium citrate, and 0.3-0.5 part of peppermint essence. By adopting the buccal tablet disclosed by the invention, the fasting blood-glucose content of the mice with the type II diabetes can be obviously reduced; the tolerance dose of oral glucose is improved; C peptide and fasting insulin level in the blood are increased. Therefore, the buccal tablet has the advantages of being convenient to take, easy to store, high in bioavailability, convenient to carry, and suitable for living demands of fast-paced people.

The invention relates to application of Kindlin-2 protein as a target spot to the preparation of medicine for treating diabetes. Research results show that expressed regions of Kindlin-2 and insulin basically coincide with each other, and the expression quantity of Kindlin-2 has closed dependency with diabetes. The mouse fasting insulin level is obviously lower than a control group after Kindlin-2 gene specificity is knocked out, glucose tolerance capacity is obviously reduced, but the sensibility to insulin of peripheral tissue after the is Kindlin-2 gene specificity is knocked out is not obviously different from that to insulin of peripheral tissue when the Kindlin-2 gene specificity is not knocked out, so that Kindlin-2 can serve as a new target spot of medicine for treating diabetes.

The invention discloses a method, device, storage medium and electronic equipment for determining an insulin resistance index. The method includes: obtaining a plurality of sample data, and recording the test indicators corresponding to insulin resistance in the sample data; constructing an evaluation model, and the evaluation model includes a first An initial model and a second initial model, there are multiple first initial models; each first initial model is trained through a plurality of sample data, and multiple first models are screened from the first initial model according to the training results; according to the first model Train the second initial model with a plurality of sample data to obtain the second model; determine the insulin of the target user through the first model and the second model, the fasting insulin concentration and the fasting blood glucose concentration according to the test index corresponding to the target user's insulin resistance resistance index. The characterization effect of the insulin resistance index determined by the method of the invention is good, and the time and cost are low.